Introduction {#s1}
============

Atopic dermatitis (AD) is a commonly diagnosed skin condition characterized by a heterogeneous pathogenesis such as chronic inflammation, barrier dysfunction, and pruritus ([@B34]). AD generally begins in early childhood and affects 10% to 25% of children and 2% to 10% of adults ([@B30]). The barrier deficiency caused by AD has been linked to increased bacterial infection in the skin ([@B36]). More than 90% of AD patients are colonized with *Staphylococcus aureus* ([@B32]). The emergence of methicillin-resistant *S. aureus* (MRSA) has led to an increase in AD exacerbation due to its resistance to current antibiotics ([@B35]). It is reported that \>700,000 people die each year because of infection by resistant microbes ([@B17]). The increasing resistance of bacteria in AD and the deteriorated inflammation advocate the demand for novel anti-MRSA and anti-inflammatory agents for AD treatment.

Some investigations have acknowledged that natural products are rich sources of antibacterial and anti-inflammatory potencies. *Antrodia cinnamomea* is a fungus inhabiting the inner cavity of *Cinnamomum kanehirae* Hayata. It is a traditional medicine for treating hypertension, cirrhosis, hepatoma, diarrhea, and itchy skin ([@B18]). The main active ingredients in *A. cinnamomea* include terpenoids, lignans, polysaccharides, and benzenoids. The extracts and compounds of *A. cinnamomea* demonstrate the capability to inhibit skin inflammation ([@B3]; [@B38]; [@B23]). The constituents from *A. cinnamomea* are reported to show antimicrobial activity against both Gram-positive and Gram-negative species ([@B19]; [@B8]; [@B26]). We previously isolated a series of benzenoids from *A. cinnamomea* and found the anti-inflammatory activity in stimulated macrophages *via* inducible nitric oxide synthase (iNOS) inhibition ([@B43]; [@B49]). Some scientists have also shown the usefulness of benzenoids from *A. cinnamomea* in suppressing inflammatory response ([@B7]; [@B6]; [@B48]). Since AD is associated with inflammation, barrier deficiency, and bacterial infection, combined therapy with anti-inflammatory and antibacterial agents can be beneficial to alleviating the symptoms. Since *A. cinnamomea* effectively inhibits inflammation and bacterial growth, it is an ideal candidate for the development of anti-AD agents. We aimed to isolate benzenoid derivatives from *A. cinnamomea* to evaluate the capability to ameliorate AD through the reduction of inflammation and the MRSA burden. Our results exhibited that among all benzenoids tested, 2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q~0~, CoQ~0~) was the most effective antibacterial compound. Using human keratinocytes as the cell model, we demonstrated that CoQ~0~ could reduce the up-regulation of cytokines and chemokines. CoQ~0~ could also enhance the decrease in TJ-related proteins caused by keratinocyte stimulation. Here, we showed that topical CoQ~0~ administration remarkably improved AD symptoms and the associated MRSA burden in the mouse model.

Materials and Methods {#s2}
=====================

Compounds {#s2_1}
---------

The agar-cultured mycelium of *A. cinnamomea* was used to prepare the extract in 95% ethanol for 3 days at room temperature. The mycelium of *A. cinnamomea* in an agar plate is shown in [**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}. A voucher specimen of *A. cinnamomea* has been deposited at the herbarium of the Institute of Fisheries Science, National Taiwan University. The fermentation of *A. cinnamomea* and the extraction and isolation of benzenoids were the same as in the previous study ([@B43]). All compounds were identified by nuclear magnetic resonance (NMR) and mass spectrometry. As shown in [**Figure 1A**](#f1){ref-type="fig"}, the following six benzenoid analogs were obtained and identified: 2,4-dimethoxy-6-methylbenzene-1,3-diol (compound 1), 6-methyl-2,3,4-trimethoxyphenol (compound 2), CoQ~0~ (compound 3), 2-methoxy-6-methylbenzene-1,4-diol (compound 4), 2,3-(methylenedioxy)-6-methylbenzene-1,4-diol (compound 5), and 1,4-dimethoxy-2,3-methylenedioxy-5-methylbenzene (compound 6). The spectra of ^1^H NMR for all compounds are shown in [**Supplementary Figure 2**](#SM2){ref-type="supplementary-material"}. The purity of all compounds was over 98%. The profiles of spectrometry of each compound are listed below.

![Determination of the antibacterial activity of *A. cinnamomea* extracted benzenoids. **(A)** The chemical structures of the benzenoids. **(B)** Zone of inhibition of MRSA treated by benzenoids measured from agar diffusion assay. **(C)** Zone of inhibition of MRSA, *S. aureus*, and VISA treated by CoQ~0~ measured from agar diffusion assay. **(D)** The growth curves of MRSA treated by CoQ~0~ at different concentrations within 48 h. **(E)** The planktonic live/dead MRSA strain determined by flow cytometry. **(F)** The planktonic live/dead MRSA strain viewed under fluorescence microscopy. Each value represents the mean ± SEM (n *=* 4). \*\*\**p* \< 0.001; \*\**p* \< 0.01; \**p* \< 0.05.](fphar-10-01445-g001){#f1}

Compound 1: colorless crystals; UV (MeOH) λ~max~ (log ε) 285 (3.39) nm; IR (ZnSe) ν~max~ 3438, 2941, 1503, 1477, 1379, 1320, 1198, 1123, 1072, 898 cm^−1^; ^1^H NMR (CD~3~OD, 300 MHz): δ~H~ 2.11 (3H, s), 3.75 (3H, s), 3.80 (3H, s), 6.44 (1H, s); electron ionization mass spectra (EIMS) *m/z*: 184 \[M\]^+^, 105 (100), 77 (85), 71 (70).

Compound 2: amorphous powder; UV (MeOH) λ~max~ (log ε) 287 (3.57) nm; IR (ZnSe) ν~max~ 3440, 2935, 2843, 1496, 1423, 1362, 1203, 1124, 1082 cm^−1^; ^1^H NMR (CD~3~OD, 300 MHz): δ~H~ 2.15 (3H, s), 3.76 (3H, s), 3.80 (3H, s), 3.83 (3H, s), 6.50 (1H, s); EIMS *m/z*: 198 \[M\]^+^, 183 (25), 105 (44), 77 (64).

Compound 3: needles; UV (MeOH) λ~max~ (log ε) 265 (3.72) nm; IR (ZnSe) ν~max~ 2927, 2858, 1657, 1604, 1455, 1275, 1207, 1142, 1074, 887 cm^−1^; ^1^H NMR (CDCl~3~, 300 MHz): δ~H~ 2.01 (3H, d, *J* = 1.5 Hz), 3.97 (3H, s), 4.00 (3H, s), 6.42 (1H, q, *J* = 1.5 *Hz*); ESIMS *m/z*: 205 \[M + Na\]^+^.

Compound 4: colorless crystals; UV (MeOH) λ~max~ (log ε) 266 (3.82) nm; IR (ZnSe) ν~max~ 3423, 1648, 1604, 1495, 1445, 1366, 1318, 1230, 1148, 1080 cm^−1^; ^1^H NMR (CDCl~3~, 300 MHz): δ~H~ 2.18 (3H, s), 3.81 (3H, s), 6.19 (1H, d, *J* = 2.7 Hz), 6.28 (1H, d, *J* = 2.7 Hz); EIMS *m/z*: 154 \[M\]^+^, 98 (89), 71 (100).

Compound 5: colorless crystals; UV (MeOH) λ~max~ (log ε) 283 (3.26) nm; IR (ZnSe) ν~max~ 3250, 1641, 1475, 1398, 1365, 1283, 1214, 1124,1049, 1017 cm^−1^; ^1^H NMR (CD~3~OD, 300 MHz): δ~H~ 2.08 (3H, d, *J* = 0.7 Hz), 5.84 (2H, s), 6.16 (1H, q, *J* = 0.7 Hz); ESIMS *m/z*: 191 \[M + Na\]^+^.

Compound 6: colorless crystals; ^1^H NMR (CDCl~3~, 300 MHz): δ~H~ 2.16 (3H, s), 3.83 (3H, s), 3.86 (3H, s), 5.91 (2H, s), 6.28 (1H, s).

The Strains of *S. aureus* {#s2_2}
--------------------------

*S. aureus* (ATCC6538) and MRSA (ATCC33591) were purchased from American Type Culture Collection. The clinical isolates of MRSA (KM-1) and vancomycin-intermediate *S. aureus* (VISA, KV-2) were the gifts of Kaohsiung Medical University Hospital. All *S. aureus* species were grown in tryptic soy broth (TSB) at 37°C and 150 rpm.

Agar Diffusion Assay {#s2_3}
--------------------

The agar diffusion assay was carried out by inoculating the microbes at OD~600~ = 0.7 in 0.75% tryptone soya broth (TSB) agar. The mixture of microbes and agar (5 ml) was dispersed into a dish for 15 min. The compounds (1 mg/ml, 10 µl) were dropped onto the agar. The compounds were chemically stable under the conditions used. The diameter of the clear zone without bacteria was measured after a 16-h incubation.

Minimum Inhibitory Concentration and Minimum Bactericidal Concentration {#s2_4}
-----------------------------------------------------------------------

Minimum inhibitory concentration (MIC) was measured using a broth 2-fold serial dilution technique. The microbes were diluted by TSB to obtain a concentration of OD~600~ = 0.01 (2 × 10^6^ colony-forming unit (CFU)/ml). The bacteria were exposed to several dilutions of the compounds with TSB and incubated at 37°C for 20 h. The absorbance of the mixture was detected by an enzyme-linked immunosorbent assay (ELISA) reader at 595 nm. A reading of \<0.1 was recognized as MIC. The microbe suspension was diluted by phosphate-buffered saline (PBS) and plated on a TSB plate. The plate was incubated at 37°C for 20 h. The CFU was then counted. Minimum bactericidal concentration (MBC) was defined as the lowest compound concentration to kill ≥99.9% of the stains.

Growth Curve of CoQ~0~-Treated MRSA {#s2_5}
-----------------------------------

A broth dilution method was used to detect a MRSA growth curve within 48 h. CoQ~0~ at the concentration of 1.85 to 62.5 µg/ml was pipetted into TSB (200 µl) with MRSA (2 × 10^5^ CFU/ml). The real-time measurement of OD~595~ was monitored using a multimode plate reader (BioTek).

MRSA Survival Detected by Flow Cytometry and Fluorescence Microscopy {#s2_6}
--------------------------------------------------------------------

MRSA was diluted by TSB to obtain an OD~600~ of 0.1. The bacteria pellet was achieved by centrifugation at 12,000 rpm for 3 min, and then suspended in culture medium with CoQ~0~ (19--312 µg/ml). The samples were stained using a Live/Dead BacLight^®^ kit after a 2-h incubation at 37°C and 150 rpm. The samples were assayed by flow cytometry (BD Biosciences) to determine MRSA viability. Fluorescence microscopy was also applied to visualize the live and dead MRSA.

Assessing MRSA Biofilm {#s2_7}
----------------------

The construction of MRSA biofilm was described previously ([@B2]). After the CoQ~0~ (78--312 µg/ml) or cetylpyridinium chloride (CPC, 75 µg/ml) treatment for 24 h, the biofilm was rinsed using PBS to remove the loosely adherent planktonic MRSA and was then suspended in PBS. The recovered MRSA outside the biofilm and the MRSA inside the biofilm were placed in an agar plate for 24 h to count CFU. The CoQ~0~- or CPC-treated biofilm was stained using Live/Dead BacLight^®^. The 3D structure, thickness, and fluorescence of the biofilm were observed by confocal microscopy (Leica).

MRSA Morphology Visualized by Electron Microscopy {#s2_8}
-------------------------------------------------

The bacteria were grown and diluted to achieve an OD~600~ of 0.3. MRSA were treated by CoQ~0~ at 312 µg/ml for 4 h. The preparation of the samples for visualization under scanning electron microscopy (SEM) and transmission electron microscopy (TEM) was described in the previous reports ([@B2]; [@B47]).

Total Amounts of Protein, RNA, and DNA in MRSA {#s2_9}
----------------------------------------------

MRSA were grown in TSB to OD~600~ = 3. CoQ~0~ at 156 µg/ml was added to the MRSA suspension at 37°C for 4 h. The centrifuged MRSA pellet was resuspended in water. The analysis of total protein, RNA, and DNA was performed using a Bio-Rad protein assay kit, a Direct-zol RNA miniprep kit, and a Presto Mini Bacteria kit according to the respective manufacturer's instructions.

Bactericidal Mechanisms of CoQ~0~ {#s2_10}
---------------------------------

An inhibition assay against DNA polymerase, topoisomerase I, and gyrase was carried out to elucidate the possible mechanisms of anti-MRSA activity by CoQ~0~. DNA polymerase was analyzed using the anti-Taq polymerase chain reaction (PCR) approach. A wrapping assay was conducted to analyze topoisomerase and gyrase. The detailed procedures of these methods were described previously ([@B47]).

Proteomic Analysis {#s2_11}
------------------

The proteomic analysis method of MRSA with or without CoQ~0~ treatment was modified from the previous study ([@B28]). Briefly, proteins in equal amounts were collected from MRSA samples for iTRAQ labeling. The protein mixtures were digested with modified, sequencing-grade trypsin at 37°C for 16 h. The peptides were then labeled with iTRAQ reagent for 1 h, pooled, and desalted. The eluted peptides were dried by vacuum centrifugation. The labeled peptides were then resuspended with buffer and separated using a 2D LC-mass/mass system (Thermo Fisher). The detailed setup of the LC-mass/mass was described in [@B10]. The data analysis for the iTRAQ-labeled proteins was carried out using Proteome Discoverer software (Thermo Fisher). The mass/mass spectra were searched against the UniProt database using the Mascot search engine (Matrix Science). The datasets of proteomic analysis for this study can be found on the website jPOSTrepo (<http://repository.jpostdb.org/>). The accession number (announce ID) is JPST000643.

Cytotoxicity of CoQ~0~-Treated Keratinocytes {#s2_12}
--------------------------------------------

HaCaT cell line (ATCC number: PCS-200-011) was cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in 5% CO~2~ at 37°C. After CoQ~0~ incubation at 0.25 to 16 µg/ml for 24 h, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution at 5 mg/ml was added to the plate for 4 h. The formazan precipitate was solubilized with DMSO and then read by an ELISA reader at 550 nm to determine keratinocyte viability.

Activating Keratinocytes by Tumor Necrosis Factor-α and Interferon-γ {#s2_13}
--------------------------------------------------------------------

HaCaT were stimulated by **tumor necrosis factor** (TNF)-α and **interferon** (IFN)-γ (20 ng/ml) to activate the inflammatory condition. CoQ~0~ at 0.25 to 2 µg/ml was added to the cells simultaneously. After a 24-h incubation, the culture supernatant was harvested for cytokine and chemokine analysis. The cells were pipetted into the lysis buffer to gain the tight junction (TJ)-related proteins from the whole cell lysate for a Western blotting assay.

ELISA Assay {#s2_14}
-----------

The cytokines and chemokines released from keratinocytes were detected by the ELISA method. The levels of interleukin (IL)-6, chemokine (C-C motif) ligand (CCL)5, and CCL17 were measured using commercial kits (ELISA MAX Deluxe Set, BioLegend) based on the manufacturer's instructions. The detailed procedures for the ELISA assay were described in our previous study ([@B29]).

Immunoblotting Assay {#s2_15}
--------------------

The separated proteins were transferred to the nitrocellulose membrane and probed with primary antibodies against filaggrin, involucrin, integrin β1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) overnight at 4°C. The membrane was incubated with anti-rabbit monoclonal antibody for 1 h. The bound antibody was observed using enhanced chemiluminescence reagent. The protein amount was quantified by the ratio of the densitometric measurement of the proteins to the corresponding GAPDH.

Animals {#s2_16}
-------

Eight-week-old male Balb/c mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan). One-week-old male or female pigs were provided by Pigmodel Animal Technology (Miaoli, Taiwan). They were housed at an ambient temperature of 25 ± 2°C and a relative humidity of 50 ± 10% on a 12-h light/dark cycle. All animals were treated in strict accordance with the recommendations set forth in the guidelines of the Institutional Animal Care and Use Committee of Chang Gung University (CGU15-083). Food and water were given *ad libitum*. All efforts were made to attenuate suffering.

Skin Absorption of CoQ~0~ {#s2_17}
-------------------------

The *in vitro* Franz cell approach was used to determine cutaneous CoQ~0~ delivery into the skin. The excised pig skin was mounted between the donor and receptor with the stratum corneum (SC) facing the donor side. The donor was filled with 0.5 ml of CoQ~0~ (1 mg/ml) in 30% ethanol/pH 7.4 buffer. The receptor medium was the same as the vehicle in the donor. The penetration area available was 0.79 cm^2^. The receptor temperature was maintained at 37°C with a stirring rate of 600 rpm triggered by a stir bar. A 300-µl aliquot in the receptor was withdrawn at the determined intervals. At 24 h post-treatment, the skin was removed to evaluate the skin deposition of the compound. The skin was extracted by methanol in a MagNA Lyser homogenizer (Roche); then the homogenate was centrifuged at 10,000*g* for 10 min. All samples were analyzed to obtain the absorption level by high-performance liquid chromatography (HPLC). The stationary phase of HPLC was a 25-cm-long, 4-mm inner diameter reverse phase C18 column (Merck). The mobile phase consisted of methanol and double-distilled water (50:50) at a flow rate of 1 ml/min. The wavelength of the UV/visible detector was 240 nm.

Establishing a Mouse Model With Combined AD-Like Lesions and MRSA Infection {#s2_18}
---------------------------------------------------------------------------

This method was adapted from the previous study that created an animal model to simulate MRSA-infected AD-like skin ([@B46]). Briefly, the mouse was treated with an intraperitoneal injection of ovalbumin (OVA, 5.3 µg/kg) for 13 d and then topical OVA administration (5.3 µg/kg) for 3 d. MRSA with a volume of 100-µl (OD~600~ = 1) was dropped on a gauze for topical application on the dorsal skin on day 15. On days 16 and 17, 1 mg/ml CoQ~0~ with a volume of 100 µl in 15% ethanol/PBS was applied to the lesional skin. The dose of 1 mg/ml was selected for CoQ~0~, which was the same as the skin absorption test. CoQ~0~ showed facile penetration in this applied concentration. The mice were divided into different groups with 6 animals per group. The gross observation of the skin surface with or without CoQ~0~ intervention was accomplished using a handheld digital magnifier (M&T Optics). The level of transepidermal water loss (TEWL) was monitored by Tewameter^®^ (Courage and Khazaka). The lesional skin was excised to measure MRSA CFU and cytokines. The skin samples were sliced to a thickness of 5 µm for hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining. The skin slices of formalin-fixed, paraffin-embedded sections were prepared for IHC. The sections were incubated with anti-lymphocyte antigen 6 complex locus G6D (Ly6G) or anti-filaggrin antibody for 1 h at room temperature, washed with saline containing 0.5% Tween 20, and then incubated at ambient temperature with biotinylated donkey anti-goat immunoglobulin G (IgG) for 20 min. Color reaction was observed by using the Vectastatin Elite avidin-biotin complex kit (Vector Laboratories). All photomicrographs of histopathology were taken by Leica DMi8 microscopy.

Skin Tolerance of CoQ~0~ {#s2_19}
------------------------

The safety of topically applied CoQ~0~ was assessed in the skin of healthy mice. CoQ~0~ (1 mg/ml) in 15% ethanol/PBS was applied daily (600 µl) on the dorsal skin for 4 days. The TEWL and skin pH were monitored every day. The erythema quantified by colorimetry (Yokogawa) was also detected. The skin was excised for H&E staining after a 4-day treatment.

Statistical Analysis {#s2_20}
--------------------

The statistical difference in the data of the different treatments with or without CoQ~0~ was analyzed using the Kruskal-Wallis test. The *post hoc* test for checking individual differences was Dunn's test. The 0.05, 0.01, and 0.001 levels of probability were taken as statistically significant.

Results {#s3}
=======

CoQ~0~ Shows the Strongest Activity Against MRSA Among the Benzenoids {#s3_1}
---------------------------------------------------------------------

We began the antibacterial investigation by administering the benzenoids (1 mg/ml) to MRSA in agar to calculate the inhibition zone. The results illustrated in [**Figure 1B**](#f1){ref-type="fig"} demonstrate that CoQ~0~ showed the greatest MRSA inhibition, followed by compounds 4, 5, and 1. Compounds 2 and 6 had no effect on forming the clear inhibition zone. [**Table 1**](#T1){ref-type="table"} summarizes the MIC and MBC results for all compounds against MRSA. The lowest MIC and MBC (7.81 µg/ml) were exhibited in the CoQ~0~ group, followed by compounds 4 and 5. CoQ~0~ elicited a concentration-dependent inhibition of MRSA, *S. aureus*, and clinical isolates of MRSA (KM-1) and VISA (KV-2) as shown in [**Figure 1C**](#f1){ref-type="fig"}. The antimicrobial activity of CoQ~0~ against different microorganisms was also investigated using MIC and MBC. As shown in [**Table 2**](#T2){ref-type="table"}, a high antibacterial potency for CoQ~0~ was observed with MIC between 7.81 and 31.25 µg/ml.

###### 

The MIC and MBC of MRSA after treatment of *Antrodia cinnamomea* compounds.

  Compound     MIC (μg/ml)   MBC (μg/ml)
  ------------ ------------- -------------
  1            125           125
  2            250           500
  3 (CoQ~0~)   7.81          7.81
  4            15.63         31.25
  5            31.25         62.5
  6            500           500

###### 

The MIC and MBC of *S. aureus*, MRSA, KM1 clinical strain and KV2 clinical strain after treatment of CoQ~0~.

  Strain        MIC (μg/ml)   MBC (μg/ml)
  ------------- ------------- -------------
  MRSA          7.81          7.81
  *S. aureus*   15.63∼31.25   15.63∼31.25
  KM-1          31.25         31.25
  KV-2          15.63∼31.25   31.25

The growth curves realized on MRSA treated with CoQ~0~ have proved the results of the inhibition zone and MIC/MBC ([**Figure 1D**](#f1){ref-type="fig"}). CoQ~0~ suppressed MRSA viability at all concentrations tested (1.85--62.5 µg/ml) in a dose-dependent manner. CoQ~0~-treated MRSA were further stained using a Live/Dead kit to discover the survival rate by flow cytometry. The representative diagram of the live/dead strain in [**Figure 1E**](#f1){ref-type="fig"} demonstrates a negligible MRSA killing at CoQ~0~ concentrations of ≤78 µg/ml. The survival rate of 156 and 312 µg/ml was 63% and 0%, respectively. Visual confirmation of the effect of CoQ~0~ on MRSA eradication was obtained using fluorescence microscopy. In [**Figure 1F**](#f1){ref-type="fig"}, the green signal stained by SYTO9 represents live MRSA, whereas the red fluorescence stained by propidium iodide (PI) indicates bacterial membrane disruption resulting in a diffuse distribution in the cytoplasm. The green dots decreased following the increase of the CoQ~0~ concentration. However, the red dots were limited, although the concentration was significantly increased.

CoQ~0~ Inhibits Biofilm Formation {#s3_2}
---------------------------------

A biofilm increases the virulence of pathogens and their resistance to antibiotics. [**Figure 2A**](#f2){ref-type="fig"} demonstrates the corresponding number of MRSA inside the biofilm. CoQ~0~ concentration-dependently reduced the MRSA number in the biofilm. The concentration at 312 µg/ml diminished CFU by about 4 logs, leading to killing 99.99% of the MRSA population. The comparator agent CPC exhibited a reduced CFU comparable to CoQ~0~ at 312 µg/ml. The 312-µg/ml CoQ~0~ completely eradicated MRSA outside the biofilm ([**Figure 2B**](#f2){ref-type="fig"}). This effect was greater than CPC used as the positive control. The x-y-z axis image of the biofilm showed an intact structure with condensed live MRSA inside ([**Figure 2C**](#f2){ref-type="fig"}). The live MRSA markedly decreased when the biofilm was incubated in the presence of CoQ~0~. The CoQ~0~-treated biofilm became less uniform and looser and thinner than the intact biofilm. CoQ~0~ and CPC suppressed the biofilm's thickness to 45% and 48% of the control, respectively ([**Figure 2D**](#f2){ref-type="fig"}). The quantification of green intensity in the biofilm showed a significant reduction by CoQ~0~ and CPC ([**Figure 2E**](#f2){ref-type="fig"}). CPC incubation increased the red color by about 6-fold ([**Figure 2F**](#f2){ref-type="fig"}). However, the increase in red color was limited for CoQ~0~. This indicates that the bacterial-membrane disruption for the cytoplasm material leakage or exogenous material entrance was not the predominant mechanism for CoQ~0~.

![Determination of the biofilm MRSA inhibition by CoQ~0~. **(A)** MRSA CFU inside the biofilm. **(B)** MRSA CFU outside the biofilm. **(C)** The three-dimensional images of biofilm analyzed by **CLSM**. **(D)** The corresponding biofilm thickness analyzed by **CLSM**. **(E)** Quantification of green fluorescence intensity (live bacteria) of MRSA biofilm. **(F)** Quantification of red fluorescence intensity (dead bacteria) of MRSA biofilm. Each value represents the mean ± SEM (n *=* 4). \*\*\**p* \< 0.001; \*\**p* \< 0.01; \**p* \< 0.05.](fphar-10-01445-g002){#f2}

CoQ~0~ as the Inhibitor of DNA Polymerase and Topoisomerases for MRSA Eradication {#s3_3}
---------------------------------------------------------------------------------

The morphology of MRSA examined by SEM showed a minimal change after CoQ~0~ treatment ([**Figure 3A**](#f3){ref-type="fig"}). Disruption of the bacterial membrane was observed by CPC, with the presence of a rough surface, irregular shape, and some cavities. As shown in the TEM image in [**Figure 3B**](#f3){ref-type="fig"}, a large amount of cytosol was released from the porous membrane by CPC. The use of CoQ~0~ resulted in the MRSA membrane remaining intact. The total protein, total RNA, and genomic DNA of MRSA were analyzed as illustrated in [**Figures 3C--E**](#f3){ref-type="fig"}, respectively. CoQ~0~ caused a significant decrease in the total amount of protein, RNA, and DNA compared to the untreated control. DNA polymerase is a major enzyme for DNA replication in MRSA. CoQ~0~ was evaluated for targeting enzyme inhibition using the anti-Taq PCR method to observe DNA polymerase inhibition. As shown in [**Figure 3F**](#f3){ref-type="fig"}, the PCR products were lessened by CoQ~0~ in a concentration-dependent manner. The relaxing activity of topoisomerase I on MRSA was tested as shown in [**Figure 3G**](#f3){ref-type="fig"}. CoQ~0~ displayed a capacity to deactivate topoisomerase I. This result was also detectable in topoisomerase II (gyrase). [**Figure 3H**](#f3){ref-type="fig"} provides the evidence that CoQ~0~ retarded the supercoiling activity of DNA gyrase.

![Anti-MRSA mechanisms of CoQ~0~. **(A)** Morphological changes of MRSA viewed under SEM. **(B)** Morphological changes of MRSA viewed under TEM. **(C)** Total protein amount in MRSA. **(D)** Total RNA amount in MRSA. **(E)** Total DNA amount in MRSA. **(F)** Taq DNA polymerase in PCR. **(G)** Topoisomerase I in wrapping assay; **(H)** DNA gyrase in wrapping assay. Each value represents the mean ± SEM (n *=* 4). \*\*\**p* \< 0.001; \*\**p* \< 0.01.](fphar-10-01445-g003){#f3}

The qualitative and quantitative analysis of the proteomics was conducted by mass as summarized in [**Table 3**](#T3){ref-type="table"}. The top ten proteins with the highest or lowest concentration ratios to the control were selected to be shown in this table. The most upregulated protein by CoQ~0~ treatment was alkyl hydroperoxide reductase. Some ATP-related proteins such as ATP-dependent zinc metalloprotease, GrpE, nucleoside diphosphate kinase, and Clpb were upregulated by CoQ~0~. On the other hand, the ribosomal proteins including L13, S6, S4, L21, S18, and L31 were downregulated after CoQ~0~ treatment.

###### 

Quantitative proteomics by iTRAQ labeling. Differentially expressed proteins follow the treatment of CoQ~0~.

  No.    [^a^](#fnT3_1){ref-type="table-fn"}Accession   Protein                                           MW \[kDa\]   Coverage   Matchedpeptides   [^b^](#fnT3_2){ref-type="table-fn"}Ratios to control   Biological function
  ------ ---------------------------------------------- ------------------------------------------------- ------------ ---------- ----------------- ------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.    A0A0E0VTX0                                     Alkyl hydroperoxide reductase AhpD                19.9         12.35      2                 2.558                                                  Antioxidant protein with alkyl hydroperoxidase activity. Required for the reduction of the AhpC active site cysteine residues and for the regeneration of the AhpC enzyme activity.
  2\.    A0A0E0VLN4                                     ATP-dependent zinc metalloprotease FtsH           77.8         3.01       2                 2.541                                                  Acts as a processive, ATP-dependent zinc metallopeptidase for both cytoplasmic and membrane proteins. Plays a role in the quality control of integral membrane proteins.
  3\.    A0A0E0VQR7                                     Delta-lysin                                       5.1          24.44      12                2.177                                                  Hemolysis by symbiont of host erythrocytes.
  4\.    A0A0E0VPI1                                     Protein GrpE                                      24.0         31.73      7                 1.749                                                  GrpE releases ADP from DnaK; ATP binding to DnaK triggers the release of the substrate protein, thus completing the reaction cycle. Several rounds of ATP-dependent interactions between DnaJ, DnaK and GrpE are required for fully efficient folding.
  5\.    A0A0E0VNU7                                     Glutamate dehydrogenase                           47.3         24.53      12                1.742                                                  Nucleotide binding oxidoreductase activity, acting on the CH-NH2 group of donors, NAD or NADP as acceptor.
  6\.    A0A0E0VP69                                     Nucleoside diphosphate kinase                     16.6         40.94      6                 1.684                                                  Major role in the synthesis of nucleoside triphosphates other than ATP. The ATP gamma phosphate is transferred to the NDP beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate.
  7\.    A0A0E0VNX4                                     Ribosome hibernation promoting factor             22.2         16.84      3                 1.679                                                  Required for dimerization of active 70S ribosomes into 100S ribosomes; when added to monomeric 70S ribosomes stimulates formation of 100S dimeric ribosomes. Unlike E.coli, 100S ribosomes are present during exponential growth, peak during early stationary phase and then decrease (shown for strain NBRC 3060).
  8\.    A0A0E0VNY8                                     Regulatory protein Spx                            16.9         46.15      5                 1.674                                                  Interferes with activator-stimulated transcription by interaction with the RNA polymerase alpha-CTD. May function to globally reduce transcription of genes involved in growth- and development-promoting processes and to increase transcription of genes involved in thiol homeostasis, during periods of extreme stress.
  9\.    A0A0E0VRS6                                     Purine nucleoside phosphorylase DeoD-type         25.9         31.36      5                 1.626                                                  Catalysis of the reaction: purine nucleoside + phosphate = purine + alpha-D-ribose 1-phosphate. Cleavage of guanosine or inosine to respective bases and sugar-1-phosphate molecules.
  10\.   A0A0E0VMH0                                     Clpb                                              19.2         25.30      2                 1.604                                                  Part of a stress-induced multi-chaperone system, it is involved in the recovery of the cell from heat-induced damage, in cooperation with DnaK, DnaJ and GrpE. ATP binding
  11\.   A0A0E0VS50                                     50S ribosomal protein L13                         16.3         46.21      11                0.475                                                  This protein is one of the early assembly proteins of the 50S ribosomal subunit, although it is not seen to bind rRNA by itself. It is important during the early stages of 50S assembly.
  12\.   A0A0E0VL11                                     30S ribosomal protein S6                          11.6         60.20      10                0.469                                                  Binds together with S18 to 16S ribosomal RNA.
  13\.   A0A0E0VPR0                                     30S ribosomal protein S4                          23.0         41.50      9                 0.468                                                  One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.
  14\.   A0A0E0VS61                                     Translation initiation factor IF-1                8.3          25.00      2                 0.443                                                  One of the essential components for the initiation of protein synthesis. Stabilizes the binding of IF-2 and IF-3 on the 30S subunit to which N-formylmethionyl-tRNA(fMet) subsequently binds. Helps modulate mRNA selection, yielding the 30S pre-initiation complex (PIC). Upon addition of the 50S ribosomal subunit, IF-1 is released leaving the mature 70S translation initiation complex.
  15\.   A0A0E0VNV5                                     Ribonucleoside-diphosphate reductase beta chain   38.8         14.37      3                 0.424                                                  Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides
  16\.   A0A0E0VPU9                                     Glutathione peroxidase                            18.1         15.82      2                 0.409                                                  Glutathione peroxidase is the general name of an enzyme family with peroxidase activity whose main biological role is to protect the organism from oxidative damage.
  17\.   A0A0E0VQU6                                     50S ribosomal protein L21                         11.7         44.76      6                 0.400                                                  This protein binds to 23S rRNA in the presence of protein L20.
  18\.   A0A0E0VLB0                                     30S ribosomal protein S18                         9.3          20.00      2                 0.399                                                  Binds as a heterodimer with protein S6 to the central domain of the 16S rRNA, where it helps stabilize the platform of the 30S subunit.
  19\.   A0A0E0VN53                                     Cold shock protein                                7.4          78.79      12                0.395                                                  Cold shock proteins are multifunctional RNA/DNA binding proteins, characterized by the presence of one or more cold shock domains.
  20\.   A0A0E0VQS6                                     50S ribosomal protein L31 type B                  9.7          46.43      8                 0.277                                                  While neither of the L31 paralogs is essential, this protein does not seem to function as the main L31 protein. Has a higher affinity for 70S ribosomes than the zinc-containing L31 paralog; is able to displace it to varying extents, even under zinc-replete conditions.

The MS/MS spectra were searched against the UniProt database (extracted for Staphylococcus aureus) using the Mascot search engine (Matrix Science, London, UK; version 2.5).

Ratios to control indicated the fold changes in protein volume among CoQ~0~ treated samples versus MRSA samples. The top ten higher ratios mean the proteins whose expression levels were increased upon treatments of compounds, while the top ten lower ratios indicate the proteins were downregulated under the exposure to compounds.

CoQ~0~ Is Effective in Inhibiting Inflammation and Recovering TJ Deficiency in an HaCaT Model {#s3_4}
---------------------------------------------------------------------------------------------

As shown in [**Figure 4A**](#f4){ref-type="fig"}, CoQ~0~ at the concentrations of ≤2 µg/ml did not exhibit considerable toxicity toward HaCaT. This compound decreased cell viability in a concentration-dependent fashion with significance at 4, 8, and 16 µg/ml. A noncytotoxic concentration of CoQ~0~ (0.25--2 µg/ml) was taken for further studies. Cytokines and chemokines were evaluated as biomarkers of inflammatory HaCaT. As presented in [**Figure 4B**](#f4){ref-type="fig"}, combined TNF-α and IFN-γ greatly increased the level of IL-6 secreted by HaCaT compared to the level in the untreated control. The inhibition of IL-6 production was detected only at 2 µg/ml for CoQ~0~. The stimulators activated chemokines, including CCL5 and CCL17 ([**Figures 4C, D**](#f4){ref-type="fig"}). CoQ~0~ dose-dependently suppressed the CCL5 and CCL17 protein levels.

![CoQ~0~ suppresses TNF-α- and IFN-γ-stimulated cytokines/chemokines and recovers TJ-protein deficiency in HaCaT cells. **(A)** The cell viability measured by MTT assay. **(B)** IL-6 in stimulated HaCaT measured by ELISA. **(C)** CCL5 in stimulated HaCaT measured by ELISA. **(D)** CCL17 in stimulated HaCaT measured by ELISA. **(E)** Filaggrin in stimulated HaCaT measured by immunoblotting. **(F)** Involucrin in stimulated HaCaT measured by immunoblotting. **(G)** Integrin β1 in stimulated HaCaT measured by immunoblotting. Each value represents the mean ± SEM (n *=* 4). \*\*\**p* \< 0.001; \*\**p* \< 0.01; \**p* \< 0.05.](fphar-10-01445-g004){#f4}

Skin-barrier dysfunction and its deficiency are key features of AD. We examined the influence of CoQ~0~ on TJ-related proteins in the activated keratinocytes. Since TNF-α and IFN-γ as the stimulators showed a limited capacity to impair filaggrin, involucrin, and integrin β1 in HaCaT, the particulate matter (PM) pollutant standard (1649b) was utilized to achieve this aim according to the previous study ([@B25]). As illustrated in the left panel of [**Figure 4E**](#f4){ref-type="fig"}, 1649b reduced filaggrin following the increase in incubation time. As shown in the right panel of [**Figure 4E**](#f4){ref-type="fig"}, CoQ~0~ at 0.5 µg/ml was sufficient to recover filaggrin in 1649b-stimulated HaCaT to the normal baseline. The level of involucrin decreased after 1649b treatment, and CoQ~0~ could not promote involucrin production in the activated HaCaT ([**Figure 4F**](#f4){ref-type="fig"}). CoQ~0~ improved the decreased protein level of integrin β1 by 1649b ([**Figure 4G**](#f4){ref-type="fig"}).

CoQ~0~ Facilely Penetrates Into the Skin {#s3_5}
----------------------------------------

The capability of topically applied CoQ~0~ to penetrate into the skin was carried out *in vitro* in Franz cell. As presented in [**Figure 5A**](#f5){ref-type="fig"}, pig skin showed the minimal CoQ~0~ deposition because of its thicker and more rigid structure than rodent skin. The skin deposition indicated the uptake within the skin. CoQ~0~ uptake in healthy and AD-like mouse skin was 0.20 and 1.11 nmol/mg, respectively. This revealed a weak barrier of AD-like skin as proved by TJ deficiency. The tendency of CoQ~0~ penetration across the skin for three skin barriers was the same as that of the absorption into the skin reservoir ([**Figure 5B**](#f5){ref-type="fig"}).

![In vitro skin absorption of CoQ~0~ and *in vivo* topical application of CoQ~0~ against MRSA-infected AD-like lesion. **(A)** In vitro skin deposition of CoQ~0~ in Franz cell using pig, healthy mouse, and OVA-treated mouse skins. **(B)** In vitro skin permeation to receptor of CoQ~0~ in Franz cell using pig, healthy mouse, and OVA-treated mouse skins. **(C)** The gross images of mouse back skin. **(D)** The close-up imaging by handheld digital microscopy. **(E)** TEWL of mice skin. **(F)** MRSA CFU of mice skin. **(G)** Skin sections represented by H&E staining. **(H)** Skin sections represented by Ly6G staining for observing neutrophils. **(I)** Skin sections represented by filaggrin staining for observing TJ distribution. Each value represents the mean ± SEM (n *=* 6). \*\*\**p* \< 0.001; \**p* \< 0.05.](fphar-10-01445-g005){#f5}

CoQ~0~ Ameliorates MRSA-Infected AD-Like Lesions *In Vivo* {#s3_6}
----------------------------------------------------------

The AD-like lesions in the mouse model were developed by both intraperitoneal and topical OVA. MRSA were topically applied on the skin for cutaneous infection. [**Figures 5C, D**](#f5){ref-type="fig"} show the gross and microscopic appearance of en face mouse skin, respectively. MRSA infection led to the observation of the open wound and scaling. These symptoms were partly attenuated in the mice dosed with CoQ~0~. The OVA challenge displayed atopic skin symptoms, including redness, excoriation, hemorrhage, and lichenification. The MRSA-infected OVA-treated skin showed the combined appearance of infection and AD-like lesions. CoQ~0~ exhibited some lesion suppression in the MRSA-infected AD-like skin. TEWL, as an indicator of the skin-barrier nature, showed a 4-fold increase in MRSA-infected skin compared to the untreated control ([**Figure 5E**](#f5){ref-type="fig"}). As seen, CoQ~0~ recovered the TEWL of the infected skin from 22.4 to 8.7 g/h/m^2^. OVA treatment further weakened the barrier function of the infected skin. Topical CoQ~0~ administration markedly suppressed TEWL to 63% of the OVA/MRSA group. [**Figure 5F**](#f5){ref-type="fig"} depicts the MRSA count in the mouse skin with different treatments. Bacterial infection increased the MRSA burden in the skin from 0 to 5.98 × 10^5^ CFU/ml. CoQ~0~ did not reduce the MRSA load in the infected skin. Because of the impaired barrier of the OVA-treated skin, a greater MRSA amount was found in the AD-like lesions than in the intact skin. CoQ~0~ reduced the pathogen burden in the OVA/MRSA group relative to the vehicle control.

Based on histological evaluation as shown in [**Figure 5G**](#f5){ref-type="fig"}, the skin infected with MRSA exhibited the features of increased epidermis thickness and inflammatory infiltrate in the dermis. CoQ~0~ treatment on the infected skin significantly reduced these symptoms. OVA-induced AD exhibited hyperkeratosis, hypertrophy, and a thicker epidermis in the microscopic image. These symptoms were also visualized in the OVA/MRSA group accompanied with immune-cell infiltration and the possibility of MRSA accumulation in the dermis. Topical CoQ~0~ showed symptom amelioration of the MRSA-infected AD-like lesions. The epidermal thickness after CoQ~0~ treatment was 2-fold lower than the OVA/MRSA without CoQ~0~ intervention. [**Figure 5H**](#f5){ref-type="fig"} reveals neutrophil infiltration in Ly6G-stained skin. This neutrophil migration could be hindered by topical CoQ~0~. As with HaCaT filaggrin evaluation, CoQ~0~ recovered filaggrin in the upper epidermis of the MRSA-infected skin with or without OVA intervention ([**Figure 5I**](#f5){ref-type="fig"}).

We next determined the presence of the cytokines in the different groups of mice as shown in [**Figures 6A--E**](#f6){ref-type="fig"}. All cytokines were elevated by MRSA invasion, indicating the induction of cutaneous inflammation. Topical CoQ~0~ application significantly inhibited IL-1β and IFN-γ in the MRSA-infected mice. CoQ~0~-treated infected skin showed similar levels of IL-4, IL-6, and IL-10 as vehicle control after statistical assay, although the concentration with CoQ~0~ treatment was lower than that with vehicle treatment. The OVA/MRSA group generally revealed a greater increase of these cytokines than OVA or MRSA treatment alone, except the comparable IFN-γ level between the OVA/MRSA and MRSA groups. As shown in [**Figures 6B--E, C**](#f6){ref-type="fig"}oQ~0~ significantly attenuated the IL-4, IL-6, IL-10, and IFN-γ expression levels by 50%, 59%, 47%, and 62% in mouse skin with combined OVA and MRSA, respectively.

![CoQ~0~ inhibits AD-like mouse skin inflammation based on cytokine assay. **(A)** IL-1β. **(B)** IL-4. **(C)** IL-6. **(D)** IL-10. **(E)** IFN-γ. Each value represents the mean ± SEM (n *=* 6). \*\*\**p* \< 0.001; \*\**p* \< 0.01; \**p* \< 0.05.](fphar-10-01445-g006){#f6}

CoQ~0~ Elicits a Slight Skin Irritation {#s3_7}
---------------------------------------

We attempted to determine whether topical CoQ~0~ induced adverse effects on mouse skin. As depicted in [**Figure 7A**](#f7){ref-type="fig"}, no visible erythema or erosion occurred when the skin was applied with CoQ~0~ as compared to the PBS control and vehicle only (15% ethanol/PBS). A significant elevation of TEWL was found after PBS and vehicle treatments at Day 2 because of the skin hydration by water molecules ([**Figure 7B**](#f7){ref-type="fig"}). This elevation decreased after a 2-day administration. CoQ~0~ application slightly increased the TEWL value as compared to vehicle control. This increase could be classified as mild. There was no difference in the skin pH and erythema quantification between the CoQ~0~ and vehicle groups ([**Figures 7C, D**](#f7){ref-type="fig"}). The H&E-stained histology also indicated that CoQ~0~ did not irritate the skin ([**Figure 7E**](#f7){ref-type="fig"}).

![*In vivo* skin tolerance examination after a 4-day application of topically applied CoQ~0~ on mice. **(A)** The close-up imaging by handheld digital microscopy. **(B)** TEWL measurement. **(C)** Skin surface pH value. **(D)** Erythema measurement. **(E)** Skin sections represented by H&E staining. Each value represents the mean ± SEM (n *=* 6).](fphar-10-01445-g007){#f7}

Discussion {#s4}
==========

AD lesions can be infected by *S. aureus*. Management of the invasion of *S. aureus*, particularly MRSA, in AD is a major challenge in clinical conditions. Novel antibacterial and anti-inflammatory molecules are urgently needed to efficiently treat AD and the associated MRSA attack. We found that most of the benzenoid derivatives extracted from *A. cinnamomea* showed anti-MRSA activity. The anti-MRSA effect was quite different among different benzenoids. The greatest MRSA inhibition by CoQ~0~ implied that the presence of the benzoquinone structure was of utmost importance for anti-MRSA activity. We calculated the physicochemical properties of the compounds by molecular modeling as shown in the [**Supplementary Table 1**](#SM3){ref-type="supplementary-material"}. CoQ~0~ was the compound with the least lipophilicity according to Alog *P*. Decreasing the lipophilicity may be beneficial for potent MRSA inhibitory activity. Both compounds 5 and 6 had the structure of benzodioxole. Compound 5 with two hydroxyl moieties showed considerable anti-MRSA activity. The replacement of the hydroxyl groups with methoxyl groups (compound 6) eliminated the activity. The hydroxyl group or lower lipophilicity was required for benzodioxole to preserve the antimicrobial action. The increased hydroxyl group number and hydrophilicity were favorable for MRSA constraint as in the cases of compounds 7 and 8. The molecular size, hydrogen-bond number, and total polarity surface were not important to governing the anti-MRSA effect.

CoQ~0~ is one of the predominant pigments in *A. cinnamomea*. It belongs to the family of coenzyme Q consisting of a benzoquinone structure conjugated to an isoprenoid chain from C0 to C10. CoQ~0~ has the potential activity to suppress inflammation, cancer, and metabolic diseases ([@B41]). The inhibitory effect of CoQ~0~ on *S. aureus* development has also been reported in previous studies ([@B15]). CoQ~0~ showed the ability to suppress the growth of both MRSA and VISA. Since the values of MIC and MBC were approximate for MRSA and VISA treated with CoQ~0~, this compound can be classified as a bactericidal agent. The biofilm form of MRSA displayed differential gene expression and physiology compared to their planktonic form ([@B1]). The biofilm produced a barrier for antibiotic penetration, resulting in the further enhancement of drug resistance. CoQ~0~ was active in preventing biofilm MRSA growth. In the final stage of biofilm maturation, some bacteria were dispersed from the biofilm ([@B11]). Our results also showed that CoQ~0~ completely eradicated MRSA outside the biofilm. The amounts of proteins, RNA, and DNA of MRSA decreased after CoQ~0~ treatment. The results of live/dead fluorescence microscopy, biofilm visualization, SEM, and TEM excluded MRSA membrane damage by CoQ~0~. The genes related to transcription and translation, as well as the metabolic process involved in protein, RNA, and DNA synthesis, could be the anti-MRSA mechanisms of CoQ~0~. DNA polymerase and topoisomerases are the important determinants of MRSA viability and the persistence of infection ([@B24]). Our results suggested that the DNA polymerase inhibition plays a role in the ability of CoQ~0~ to impede MRSA growth.

CoQ~0~ also restrained the activity of topoisomerase I and gyrase. Both enzymes are categorized as belonging to the family of topoisomerases helping to regulate DNA topology. Topoisomerases are potential targets for many antibacterial agents ([@B39]). CoQ~0~ may inhibit the topology of DNA during transcription, replication, and recombination. This is harmful to the survival of MRSA. The catalytic mechanism of DNA gyrase is involved in the double-strand DNA cleavage in an ATP-dependent manner ([@B9]). We found that some ATP-related proteins were increased by CoQ~0~ treatment. Under the harsh stress of the CoQ~0~ attack, the MRSA bacteria produced more energy to adapt to this adversity. The mode of action of this agent could be involved in the energy production. The proteomic assay also demonstrated a downregulation of ribosomes in CoQ~0~-treated pathogens. Ribosomes are the resistance proteins working against antibiotic drugs. A critical role of ribosomes is the maintenance of the substrate stability in the process of protein synthesis ([@B14]). The inhibition of ribosomes by CoQ~0~ may be detrimental to the protein synthesis, resulting in the total-protein lessening as observed in our results. Some topoisomerases are quite different between prokaryotes and eukaryotes. Gyrase is even absent in higher eukaryotes ([@B9]). DNA topoisomerases are considered as an ideal target for anti-MRSA agents because of the minimal influence on mammalian cells. The multiple targeting to different enzymes by CoQ~0~ is advantageous to delaying the bacterial resistance because the possibility of simultaneous mutation on different targets is low.

It is worthwhile to develop the agents with combined antibacterial and anti-inflammatory actions to diminish bacteria-elicited inflammation ([@B20]). Keratinocytes are active in the immune reaction of AD by producing pro-inflammatory factors. CoQ~0~ has been reported as an anti-inflammatory agent in the cell models of endothelial cells and macrophages ([@B44]; [@B45]). The experimental results suggested that CoQ~0~ has an anti-inflammatory effect on stimulated keratinocytes through the inhibition of IL-6, CCL5, and CCL17. These cytokines and chemokines are all closely correlated to the pathogenesis and immune response of AD ([@B4]). CCL5 is an inflammatory chemokine produced in response to bacterial toxins ([@B13]). CCL5 suppression is beneficial to limiting the inflammation caused by MRSA. The downregulation of TJ proteins in infected AD skin is a result of the inflammatory response ([@B5]). TJ is involved in proliferation, differentiation, and adhesion in keratinocytes. The differentiation biomarkers filaggrin, involucrin, and integrin β1 are principal proteins in the construction of the skin-barrier property ([@B12]). CoQ~0~ could ameliorate the deficiency of filaggrin and integrin β1 but not involucrin in 1649b-treated HaCaT. This indicates the capability of CoQ~0~ to protect the skin's barrier function. This inference was verified by the TEWL and filaggrin expression in the *in vivo* mouse model.

A prerequisite for a topically applied agent showing therapeutic potential is effective permeation into the skin. Our data demonstrated the ability of CoQ~0~ to penetrate into the animal skins. The small size of CoQ~0~ (molecular weight = 182 Da) made facile permeation feasible. An optimized hydrophilic and lipophilic balance of the permeant structure is essential for achieving facile skin absorption. The higher lipophilicity causes greater delivery across the SC; however, this property may remain the permeant in the SC because of the retardation of further diffusion into viable skin ([@B27]). [@B42] claimed the hindrance of viable skin transport for the permeant with log *P* \> 2. CoQ~0~ with a log *P* of 0.51 would be suitable to diffuse across both the SC and viable skin. We found that OVA treatment greatly increased the skin penetration of CoQ~0~. Impairment of TJ led to an aberrant SC barrier associated with filaggrin inhibition and TEWL extension in the case of AD-like skin.

Immunization of the mice with OVA evokes cutaneous inflammation resembling AD ([@B22]). The presence of MRSA further increased the severity of the skin inflammation and barrier-function deficiency. The downregulation of TJ in AD is a trigger of increased *S. aureus* invasion ([@B31]). The antimicrobial peptides derived by keratinocytes are finite in AD skin ([@B21]). MRSA facilely invaded the AD lesions to produce significant colonization as detected in this study. The MRSA accumulation in the skin further damaged the epidermal barrier to allow allergen transport. AD lesions are characterized by a vicious cycle of disrupted barrier and cutaneous inflammation. The intervention to repair the barrier characteristics is useful for delaying AD progression ([@B40]). In the present study, topical CoQ~0~ protected the cutaneous barrier in AD-like skin. The upregulated CCL5 and CCL17 in AD not only caused the impaired integrity of the skin barrier but also induced immune-cell infiltration ([@B33]). Our results demonstrated that CoQ~0~ markedly diminished chemokine upregulation in keratinocytes to ameliorate the barrier function and the severity of AD inflammation. The chemokine suppression also impeded the infiltration of neutrophils to the dermis. The antibacterial activity of CoQ~0~ also restrained the MRSA load in AD-like skin. Our results illustrated that combined OVA and MRSA interventions significantly increased the expression of pro-inflammatory cytokines in mouse skin. Topically applied CoQ~0~ proved to limit the cytokines in the AD-like mouse model with MRSA invasion. This inhibition may have contributed to the amelioration of AD by decreasing immune-cell infiltration.

A concern pertaining to the application of CoQ~0~ is the safety of use. We found a cytotoxicity toward keratinocytes treated by CoQ~0~ at higher concentrations (≥7.8 µg/ml). It is reported that CoQ~0~ is toxic to mammalian cells through direct alkylation to DNA ([@B37]). Although CoQ~0~ showed some toxicity in the cell model, the *in vivo* skin-tolerance study manifested slight-to-mild skin irritation because the barrier function was disturbed in healthy mice. Whether CoQ~0~ exhibits a safe therapeutic index remains to be elucidated. A future strategy to resolve the irritation could be the design and optimization of the vehicles for CoQ~0~ to shield the possible toxicity. For AD management, combined corticosteroids and antibiotics have reportedly been successful ([@B16]). However, topical corticosteroids induce skin thinning to compromise skin damage and increase the sensitivity to allergens and *S. aureus*. The use of multiple drugs usually contributes to patient noncompliance. The combined anti-MRSA and anti-inflammatory activities of CoQ~0~ may be useful to resolving these drawbacks.

Conclusions {#s5}
===========

The resulting compound from *A. cinnamomea* was tested for possible candidacy as an anti-AD agent capable of eradicating MRSA and suppressing skin inflammation. The results indicated that CoQ~0~ has a potential anti-MRSA effect against both the planktonic and biofilm forms. The antibacterial mechanism of CoQ~0~ could be the inhibition of DNA polymerase and topoisomerases. The proteomic analysis also exhibited a significant decrease of ribosomal proteins in the MRSA treated by CoQ~0~. A downregulation of cytokines and chemokines and the recovery of TJ-related proteins were observed in stimulated keratinocytes after CoQ~0~ treatment. Facile CoQ~0~ delivery into the skin led to the amelioration of AD-like lesions in an *in vivo* model. This compound also reduced the MRSA burden in the experimental AD skin. Taken together, our findings suggest the potential of topical CoQ~0~ as a new therapeutic option for the treatment of bacteria-infected AD.
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